Resources

Contraceptive Pearl: Understanding the Differences Between Combined and Progestin-only Oral Contraceptives

Written by Sairah Cherian, Pharm.D. and Regina Ginzburg, Pharm.D., CDCES, BC-ADM

Combined oral contraceptives (COC) consist of an estrogen and progestin and work synergistically to prevent pregnancy. Progestin is the main component of contraception and suppresses ovulation by decreasing luteinizing hormone. It also thickens the cervical mucus to inhibit sperm penetration, and thins the uterine lining to prevent egg implantation.1,2 Estrogen stabilizes the endometrium and reduces irregular bleeding. Monophasic COCs contain the same amounts of estrogen and progestin throughout the active pills, whereas multiphasic COCs contain variable amounts of the hormones in an attempt to mimic the body’s hormone fluctuations. Although both are equally effective, monophasic tablets may be preferred because adverse effects are easier to identify and manage, and it’s easier to induce amenorrhea than with multiphasic formulations.2 All COC types have a more lenient missed dosing regimen compared to traditional progestin-only pills (POPs), where the medication can be taken any time within 24 hours of the missed dose. 

POPs contain either norethindrone, norgestrel, or drospirenone. These are synthetic hormones derived from testosterone, progesterone, or spironolactone.2,3 They remain a viable option for patients who cannot take estrogen due to its contraindications. Norethindrone POPs are commonly prescribed due to their long-standing safety and efficacy, as well as its low cost. More recently, the FDA approved norgestrel POP as an over-the-counter medication.4 Norethindrone and norgestrel POPs require a stricter dosing schedule and should be taken at the same time every day to maintain effectiveness. This is because the drug peaks at 2 hours but returns to near baseline at ~24 hours.5 If taken past 3 hours of its scheduled time, backup contraception is needed.5,6 Drospirenone POPs are newer and have both antiandrogenic and antimineralocorticoid effects, which can help improve acne and bloating, but are more expensive. Drospirenone POPs also suppress ovulation, which provides a longer missed pill window of 24 hours, allowing greater flexibility compared with norethindrone. People may experience more unpredictable bleeding compared to COCs.  

Choosing the right oral contraceptive depends on specific patient factors. Understanding the differences among the estrogen and progestin components of oral contraceptives can guide providers and patients in selecting the most appropriate option. The table provides examples of various oral contraceptive types. 

Formulation Type Brand name examples Estrogen composition Progestin composition
Monophasic Alesse, Aviane, Lutera 20 μg ethinyl estradiol 0.1 mg levonorgestrel
Jolessa, Levora, Nordette, Portia, Quasense, Seasonale 30 μg ethinyl estradiol 0.15 mg levonorgestrel
Apri, Desogen, Reclipsen 30 μg ethinyl estradiol 0.15 mg desogestrel
Junel 21 1/20, Loestrin 21 1/20, Microgestin 1/20 20 μg ethinyl estradiol 1 mg norethindrone
Junel 21 1.5/30, Loestrin 21 1.5/30, Microgestin 1.5/30 30 μg ethinyl estradiol 1.5 mg norethindrone
Balziva, Femcom Fe, Ovcon 35 35 μg ethinyl estradiol 0.4 mg norethindrone
Brevicon, Modicon, Necon 0.5/35 35 μg ethinyl estradiol 0.5 mg norethindrone
Necon 1/35, Norinyl 1/35, Ortho-Novum 1/35 35 μg ethinyl estradiol 1 mg norethindrone
Necon 1/50, Ovcon 50 50 μg ethinyl estradiol 1 mg norethindrone
Cryselle, Lo/Ovral, Low-Ogestrel 30 μg ethinyl estradiol 0.3 mg norgestrel
MonoNessa, Ortho-Cyclen, Previfem, Sprintec 35 μg ethinyl estradiol 0.25 mg norgestimate
Yaz 20 μg ethinyl estradiol 3 mg drospirenone
Ocella, Yasmin 30 μg ethinyl estradiol 3 mg drospirenone
Kelnor, Zovia 1/35 35 μg ethinyl estradiol 1 mg ethynodiol
Zovia 1/50 50 μg ethinyl estradiol 1 mg ethynodiol
Ortho-Cept 30 μg ethinyl estradiol 0.15 mg desogestrel
Lybrel 20 μg ethinyl estradiol 0.09 mg levonorgestrel
Seasonique 30 μg ethinyl estradiol; 10 μg ethinyl estradiol 0.15 mg levonorgestrel
Norinyl 1/50 50 μg mestranol 1 mg norethindrone
Multiphasic Cyclessa, Caziant, Velivet 25 μg ethinyl estradiol 0.1, 0.125, 0.15 mg desogestrel
Enpresse, Trivora, Levonest, Myzilra 30 μg/40 μg/30 μg ethinyl estradiol 0.05 mg,0.075 mg,/0.125 mg levonorgestrel
Ortho Tri-Cyclen Lo, Tri-Lo- Estarylla, Tri-Lo-Marzia, Tri-Lo-Mili, Tri-Lo-Sprintec 25 μg ethinyl estradiol 0.18, 0.215, 0.25 mg norgestimate
Ortho Tri-Cyclen, Tri-Previfem, Tri-Sprintec, TriNessa 35 μg ethinyl estradiol 0.18, 0.215, 0.25 mg norgestimate
Necon 7/7/7, Ortho-Novum 7/7/7, Cyclafem 7/7/7, Dasetta 7/7/7 35 μg ethinyl estradiol 0.5, 0.75, 1 mg norethindrone
Aranelle, Tri-Norinyl 35 μg ethinyl estradiol 0.5, 1, 0.5 mg norethindrone
Progestin-Only Camila, Deblitane, Errin, Heather, Jencycla, Ortho Micronor   0.35 mg norethindrone
Opill   0.075 mg norgestrel
Slynd   4 mg drospirenone

RHAP Resources:

Your Birth Control Choices Fact Sheet

Pill User Guide

Progestin-Only Pill (POP) User Guide

Download and print our resources for free from our website or visit our store to buy physical copies!


Partner Resources:

Reproductive Health Hotline (ReproHH): A free, confidential phone service (1-844-737-7644) offering evidence-based clinical information for healthcare providers across the US who have questions related to sexual and reproductive health.


Sources:

1. Cooper DB, Patel P. Oral Contraceptive Pills. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430882/

2. Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA. 2021;326(24):2507-2518. doi:10.1001/jama.2021.21392

3. Regidor PA. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9(77):34628-34638. Published 2018 Oct 2. doi:10.18632/oncotarget.26015

4. Food and Drug Administration. FDA Approves First Nonprescription Daily Oral Contraceptive. FDA News Release. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive Accessed May 26, 2026.

5. Curtis KM, Nguyen AT, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(3):1-77Available at: https://www.cdc.gov/mmwr/volumes/73/rr/rr7303a1.htm

6. El-Ibiary SY. Contraception. In: Haines ST, Nolin TD, Ellingrod VL, Posey L, Cocohoba J, Holle L. eds. DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 13th Edition. McGraw Hill; 2026. Accessed May 26, 2026. 


Sign up to Receive Contraceptive Pearls Monthly!

If you enjoyed this Contraceptive Pearl, sign up to have them delivered to your inbox! Contraceptive Pearls are released on the third Tuesday of every month!


Sign up to Receive Insights Monthly!

If you enjoyed this Pearl article, then check out Insights! Insights are monthly e-newsletters offering primary care clinicians evidence-based education on abortion and early pregnancy loss care (miscarriage). Read our latest Insights on our website. You can sign up to have Insights delivered to your inbox! Insights are released on the fourth Tuesday of every month!


Pharma-free: The Reproductive Health Access Project does not accept funding from pharmaceutical companies. We do not promote specific brands of medication or products. The information in the Pearls is unbiased, based on science alone.